Role for chymase in heart failure: Angiotensin II-dependent or -independent mechanisms?

Circulation

Volumn 107, Issue 20, 2003, Pages 2522-2524

  Kokkonen, Jorma O ^b   Lindstedt, Ken A ^b   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b NONE

Author keywords

Angiotensin; Editorials; Heart failure

Indexed keywords

ANGIOTENSIN; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE;

CELL STIMULATION; EDITORIAL; HEART FAILURE; HUMAN; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHYMASES; DISEASE MODELS, ANIMAL; DOGS; ENZYME INHIBITORS; EXTRACELLULAR SPACE; HEART FAILURE, CONGESTIVE; HUMANS; MAST CELLS; MICE; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; SERINE ENDOPEPTIDASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0038012831     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000074786.92067.AA     Document Type: Editorial

References (20)

1. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing hearts. Circ Res. 1990;66:883-890.
2. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid: inhibition of chymase by protease inhibitors of the interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation. 1997;95:1455-1463.
3. Balcells E, Meng QC, Johnson WH Jr, et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273:H1769-H1774.
4. Akusu M, Urata H, Kinoshita A, et al. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 1998;32:514-520.
5. Balcells E, Meng QC, Hageman G, et al. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol. 1996;271:H417-H421.
6. Wei C-C, Meng QC, Palmer R, et al. Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation. 1999;99:2583-2589.
7. Dell'Italia LJ, Balcells E, Meng QC, et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol. 1997;273:H961-H970.
8. Su X, Wei CC, Machida N, et al. Differential expression of angiotensin converting enzyme and chymase in dogs with chronic mitral regurgitation. J Mol Cell Cardiol. 1999;31:1033-1045.
9. Zisman LS, Abraham WT, Meixell GE, et al. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995;95:1490-1498.
10. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
11. Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97:971-978.
12. Frangogiannis NG, Perrard JL, Mendoza LH, et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation. 1998;98:687-698.
13. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
14. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Study Group. Lancet. 2002;360:752-760.
15. Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555-2558.
16. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375-381.
17. Taipale J, Lohi J, Saarinen J, et al. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem. 1995;270:4689-4696.
18. Lindstedt KA, Wang Y, Shiota N, et al. Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J. 2001;15:1377-1388.
19. Longley BJ, Tyrrell L, Ma Y, et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA. 1997;94:9017-9021.
20. Sukenaga Y, Kamoshita K, Takai S, et al. Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. Jpn J Pharmacol. 2002;90:218-222.